Equine VLP-1 antibody and antigen (recombinant protein)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-EQU-VLP-1-Ag01	Recombinant Equine VLP-1 protein	3090
GMP-EQU-VLP-1-Ab01	Anti-Equine VLP-1 mouse monoclonal antibody (mAb)	1953
GMP-EQU-VLP-1-Ab02	Anti-Equine VLP-1 mouse monoclonal antibody (mAb)	1953
GMP-EQU-VLP-1-Ab03	Anti-Equine VLP-1 human monoclonal antibody (mAb)	1953
GMP-EQU-VLP-1-Ab04	Anti-Equine VLP-1 human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-EQU-VLP-1-Ag01
Product Name	Recombinant Equine VLP-1 protein
Target/Biomarker	Equine Visinin-like protein 1 (VLP-1)
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Equine Visinin-like protein 1 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in VLP-1 level test of animal Equine/Horse with Alzheimer Disease(AD).
Tag	His
Products description	Recombinant Equine VLP-1 protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-EQU-VLP-1-Ab01, GMP-EQU-VLP-1-Ab02
Product Name	Anti-Equine VLP-1 mouse monoclonal antibody (mAb)
Target/Biomarker	Equine Visinin-like protein 1 (VLP-1)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Equine Visinin-like protein 1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-VLP-1 antibodies in VLP-1 level test of animal Equine/Horse with Alzheimer Disease(AD).
Tag	mFc
Products description	Anti-Equine VLP-1 mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-VLP-1 antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-EQU-VLP-1-Ab03, GMP-EQU-VLP-1-Ab04
Product Name	Anti-Equine VLP-1 human monoclonal antibody (mAb)
Target/Biomarker	Equine Visinin-like protein 1 (VLP-1)
Expression platform	CHO
Isotypes	Human IgG1
Bioactivity validation	Recombinant Equine Visinin-like protein 1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-VLP-1 antibodies in VLP-1 level test of animal Equine/Horse with Alzheimer Disease(AD).
Tag	hFc
Products description	Anti-Equine VLP-1 human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-VLP-1 antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Equine Vaccinia-Like Particles-1 (VLP-1) assumes a captivating role within the intricate tapestry of equine immunology. At its core, VLP-1 is a remarkable molecular structure, resembling viral particles, yet devoid of the genetic material necessary for viral replication. Structurally, it primarily consists of protein subunits that encapsulate fragments of equine DNA. VLP-1's significance transcends its structural resemblance to viruses. Instead, it plays a pivotal role in the equine immune response, particularly in the context of viral infections and vaccinations. When horses encounter viral pathogens or receive vaccines, their immune system orchestrates a coordinated defense. Part of this intricate defense involves the synthesis and release of VLP-1 by immune cells. This biomarker serves as a molecular beacon, signaling the activation of the immune system, particularly in response to viral antigens. Notably, VLP-1 is not a disease-causing entity; rather, it functions as an amplifier of the equine immune response. Its virus-like appearance acts as a catalyst, fostering a robust immunological reaction. This process primes the equine immune system, preparing it to recognize and combat actual viral threats with heightened efficiency. It is a cornerstone of the equine immune defense against viral adversaries.

About GDU